Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)
CompletedOBSERVATIONAL
Enrollment
229
Participants
Timeline
Start Date
February 28, 2014
Primary Completion Date
July 31, 2019
Study Completion Date
October 29, 2019
Conditions
Metastatic Gastrointestinal CancerGenitourinary Cancer
Trial Locations (1)
99999
Samsung Medical Center, Seoul
All Listed Sponsors
lead
Samsung Medical Center
OTHER
NCT02140463 - Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial) | Biotech Hunter | Biotech Hunter